Overview

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Status:
Suspended
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Treatments:
Gefitinib